NCT01580488

A Plaque Test Study With LEO 35299 in Psoriasis Vulgaris

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: LEO Pharma · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to evaluate the anti-psoriatic effect of LEO 35299 in different formulations, compared to Daivonex® ointment and Daivonex® ointment vehicle, using the psoriasis plaque test modified from the method developed by KJ Dumas and JR Scholtz.

Conditions

• Psoriasis Vulgaris

Interventions

Type	Name	Description
DRUG	B LEO 35299 20 mg/g cream	once daily application, 3 weeks
DRUG	C LEO 35299 20 mg/g cream	once daily application, 3 weeks
DRUG	E LEO 35299 10 mg/g solution	once daily application, 3 weeks
DRUG	F LEO 35299 10 mg/g solution	once daily application, 3 weeks
DRUG	Daivonex® ointment	once daily application, 3 weeks
DRUG	Daivonex® ointment vehicle	once daily application, 3 weeks

Timeline

• Start date: 2012-04-01
• Primary completion: 2012-06-01
• Completion: 2012-06-01
• First posted: 2012-04-19
• Last updated: 2025-03-12
• Results posted: 2013-12-30

Locations

1 site across 1 country: France